Ultragenyx Pharmaceutical

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. It is creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. The Company believes that it can deliver significant value to its patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine. 

Company Growth (employees)
Novato, US
Size (employees)
376 (est)
Ultragenyx Pharmaceutical was founded in 2010 and is headquartered in Novato, US

Ultragenyx Pharmaceutical Office Locations

Ultragenyx Pharmaceutical has an office in Novato
Novato, US (HQ)
60 Leveroni Ct

Ultragenyx Pharmaceutical Financials and Metrics

Ultragenyx Pharmaceutical Financials

Ultragenyx Pharmaceutical's revenue was reported to be $133 k in FY, 2016

Revenue (Q2, 2017)

17 k

Net income (Q2, 2017)

(72.9 m)

EBIT (Q2, 2017)

(78.4 m)

Market capitalization (11-Dec-2017)

1.9 b

Cash (30-Jun-2017)

90.8 m
Ultragenyx Pharmaceutical's current market capitalization is $1.9 b.
USDFY, 2014FY, 2015FY, 2016


133 k

R&D expense

46 m114.7 m183.2 m

General and administrative expense

10.8 m33 m64.9 m

Operating expense total

56.8 m147.7 m248.1 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


17 k111 k17 k

R&D expense

17.4 m23.1 m29.7 m40.4 m43.3 m48.7 m51.3 m58.4 m

General and administrative expense

4.1 m7 m10.2 m13.2 m14.7 m17.2 m18.7 m20 m

Operating expense total

21.5 m30.1 m39.9 m53.6 m58.1 m65.9 m70 m78.4 m
USDFY, 2014FY, 2015FY, 2016


24.3 m93.6 m161.1 m


5.9 m13.1 m20.1 m

Current Assets

193.4 m450.2 m401.7 m


3 m7.4 m17.1 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


178 m52.4 m166.7 m70.8 m55.1 m142.3 m159.5 m90.8 m

Current Assets

350.5 m336.5 m460.7 m430.2 m411.1 m416.8 m444.7 m419.8 m


3.5 m4.8 m6.3 m13.4 m17.1 m18.2 m16.5 m16.4 m

Total Assets

355.8 m343 m602.1 m524.2 m482 m515.2 m545.8 m497.5 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(59.8 m)(145.6 m)(245.9 m)

Depreciation and Amortization

684 k1.4 m3.4 m


(4.1 m)(7.1 m)(7.1 m)

Accounts Payable

3.2 m(2 m)2.5 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(21.4 m)(29.8 m)(39.2 m)(52.8 m)(56.9 m)(64.9 m)(68.3 m)

Accounts Payable

3.5 m3.6 m4.2 m5.8 m10.2 m4.4 m6 m7 m6.6 m8.3 m
USDY, 2017



Financial Leverage

1.2 x
Show all financial metrics

Ultragenyx Pharmaceutical Market Value History

Ultragenyx Pharmaceutical's Web-traffic and Trends

Ultragenyx Pharmaceutical Company Life and Culture

You may also be interested in